Early-stage glottic cancer Cancer on vocal cords
Conditions
Interventions
Patients who are able to meet the pre-treatment dose constraints will be treated with 5 fractions divided in 2-3 weeks. The primary tumor will be treated with 5x8.5 Gy (42.5 Gy). Doses on the laryngea
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Squamous cell carcinoma of the glottic larynx, cT1-2 N0M0 stage, indication for curative radiotherapie
Exclusion criteria
Exclusion criteria: Concurrent chemotherapy or cetuximab, smoking at the time of treatment, patients unsuited for MRI-imaging, pre-treatment dosimetric constraints are not met, malignant tumor(s) at another site, previous malignancies in the HN region treated with surgery (excluding microlaryngoscopy (MLS)), chemotherapy or radiotherapy, age < 18 years, participation in another interventional study, mental or physical impairment causing the participant to be unable to fill out questionnaires. Patients who had a diagnostic or therapeutic MLS can be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of fractions successfully performed on MR-Linac and the safety of the treatment looking at grade 3 late toxicity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient safety, toxicity and tolerability of this treatment concept. | — |
Countries
Netherlands
Contacts
Public ContactM. de Ridder
Universitair Medisch Centrum Utrecht
Outcome results
None listed